Who would have thought a single Ki67 measurement would predict long-term outcome?

Breast Cancer Research

Volumn 11, Issue SUPPL. 3, 2009, Pages

  Dowsett, Mitch ^a,b   A'Hern, Roger ^b   Salter, Janine ^a,b   Zabaglo, Lila ^a,b   Smith, Ian E ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; KI 67 ANTIGEN; LETROZOLE; TAMOXIFEN;

ARTICLE; BREAST CARCINOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER SURGERY; HUMAN; MEASUREMENT; MONOTHERAPY; OUTCOME ASSESSMENT; PROGNOSIS; ADJUVANT THERAPY; BREAST TUMOR; FEMALE; METABOLISM; PREDICTION AND FORECASTING; TIME; TREATMENT OUTCOME;

BREAST NEOPLASMS; FEMALE; HUMANS; KI-67 ANTIGEN; NEOADJUVANT THERAPY; PREDICTIVE VALUE OF TESTS; PROGNOSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 77951932714     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr2434     Document Type: Article

References (9)

1. Zabaglo L, Salter J, Anderson H, Hills M, A'Hern R, Dowsett M. Comparative validation of the SP6 and MIB1 antibodies to Ki67 and their use in tissue microarray (TMA) and image analysis for breast cancer. San Antonio Breast Cancer Symposium; 9-13 December San Antonio, Texas, USA. Abstracts will be published as a supplement to Cancer Research 2009, AACR, Philadelphia.
2. Dowsett M, Smith IE, Ebbs SR, Dixon JM, Skene A, Griffith C, Boeddinghaus I, Salter J, Detre S, Hills M, Ashley S, Francis S, Walsh G. Short-term changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival. Clin Cancer Res 2005, 11(2 Pt 2):951s-958s.
3. Dowsett M, Smith IE, Ebbs SR, Dixon JM, Skene A, A'Hern R, Salter J, Detre S, Hills M, Walsh G. Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer. J Natl Cancer Inst 2007, 99:167-170. 10.1093/jnci/djk020, 17228000.
4. Ellis MJ, Coop A, Singh B, Tao Y, Llombart-Cussac A, Janicke F, Mauriac L, Quebe-Fehling E, Chaudri-Ross HA, Evans DB, Miller WR. Letrozole inhibits tumor proliferation more effectively than tamoxifen independent of HER1/2 expression status. Cancer Res 2003, 63:6523-6531.
5. Jones RL, Salter J, A'Hern R, Nerurkar A, Parton M, Reis-Filho JS, Smith IE, Dowsett M. The prognostic significance of Ki67 before and after neoadjuvant chemotherapy in breast cancer. Breast Cancer Res Treat 2009, 116:53-68. 10.1007/s10549-008-0081-7, 18592370.
6. Urruticoechea A, Smith IE, Dowsett M. Proliferation marker Ki-67 in early breast cancer. J Clin Oncol 2005, 23:7212-7220. 10.1200/JCO.2005.07.501, 16192605.
7. Desmedt C, Haibe-Kains B, Wirapati P, Buyse M, Larsimont D, Bontempi G, Delorenzi M, Piccart M, Sotiriou C. Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes. Clin Cancer Res 2008, 14:5158-5165. 10.1158/1078-0432.CCR-07-4756, 18698033.
8. Early Breast Cancer Trialists Collaborative Group Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005, 365:1687-1717. 10.1016/S0140-6736(05)66544-0, 15894097, Early Breast Cancer Trialists Collaborative Group.
9. Dowsett M, Cuzick J, Ingle JN, Coates A, Forbes JF, Bliss JM, Buyse M, Baum M, Buzdar AU, Colleoni M, Coombes C, Snowdon C, Gnant MFX, Jakesz R, Kaufmann M, Boccardo F, Godwin J, Davies C, Peto R. Meta-analyses of breast cancer outcomes in adjuvant trials of aromatase ihibitors versus tamoxifen. J Clin Onco 2009,